Literature DB >> 2272029

Novel anthracycline analogs.

M Grandi1, G Pezzoni, D Ballinari, L Capolongo, A Suarato, A Bargiotti, D Faiardi, F Spreafico.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2272029     DOI： 10.1016/0305-7372(90)90037-g

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  11 in total

1.  Engineered biosynthesis of aklanonic acid analogues.

Authors:  Taek Soon Lee; Chaitan Khosla; Yi Tang
Journal:  J Am Chem Soc       Date:  2005-09-07       Impact factor: 15.419

2.  Morpholinylanthracyclines: cytotoxicity and antitumor activity of differently modified derivatives.

Authors:  M Ripamonti; L Capolongo; G Melegaro; C Gornati; A Bargiotti; M Caruso; M Grandi; A Suarato
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

3.  The role of methoxymorpholino anthracycline and cyanomorpholino anthracycline in a sensitive small-cell lung-cancer cell line and its multidrug-resistant but P-glycoprotein-negative and cisplatin-resistant counterparts.

Authors:  W T van der Graaf; N H Mulder; C Meijer; E G de Vries
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

4.  Effects of the methoxymorpholino derivative of doxorubicin and its bioactivated form versus doxorubicin on human leukemia and lymphoma cell lines and normal bone marrow.

Authors:  J S Kühl; G E Durán; N J Chao; B I Sikic
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

5.  Immunodepressive activity of FCE 23762 on humoral and cell-mediated immune responses in normal mice: comparison with doxorubicin.

Authors:  M C Fornasiero; M Ferrari; P Gnocchi; D Trizio; A M Isetta
Journal:  Agents Actions       Date:  1992-11

6.  Growth-inhibitory properties of novel anthracyclines in human leukemic cell lines expressing either Pgp-MDR or at-MDR.

Authors:  M Mariani; L Capolongo; A Suarato; A Bargiotti; N Mongelli; M Grandi; W T Beck
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

7.  Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients.

Authors:  M Bakker; J P Droz; A R Hanauske; J Verweij; A T van Oosterom; H J Groen; M A Pacciarini; L Domenigoni; F van Weissenbruch; E Pianezzola; E G de Vries
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

8.  In vivo anti-tumour activity of FCE 23762, a methoxymorpholinyl derivative of doxorubicin active on doxorubicin-resistant tumour cells.

Authors:  M Ripamonti; G Pezzoni; E Pesenti; A Pastori; M Farao; A Bargiotti; A Suarato; F Spreafico; M Grandi
Journal:  Br J Cancer       Date:  1992-05       Impact factor: 7.640

9.  L1210 cells selected for resistance to methoxymorpholinyl doxorubicin appear specifically resistant to this class of morpholinyl derivatives.

Authors:  C Geroni; E Pesenti; M Broggini; G Belvedere; G Tagliabue; M D'Incalci; G Pennella; M Grandi
Journal:  Br J Cancer       Date:  1994-02       Impact factor: 7.640

10.  Metabolic conversion of methoxymorpholinyl doxorubicin: from a DNA strand breaker to a DNA cross-linker.

Authors:  D H Lau; G E Duran; A D Lewis; B I Sikic
Journal:  Br J Cancer       Date:  1994-07       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.